Infinitopes, a CRUK-led biotech spinout in collaboration with Oxford University, has developed a highly novel, patented anti-metastatic vaccine that can be combined with surgery and adjuvant chemotherapy to prevent metastases.

Cancer vaccines that can generate high-magnitude immune responses directed to tumour-specific antigens represent promising novel cancer therapies. However, existing approaches have failed to succeed due to poor treatment regimens, suboptimal vaccine delivery platforms and poor selection of tumour antigens.

Preclinical studies have demonstrated our vaccine can confer unprecedented long-term protection and absolute suppression of metastases in multiple tumour models. Infinitopes is a unique collaboration of world-leading cancer doctors, immunologists and vaccine experts who will be starting Phase I/IIa human trials mid 2024.